Premium
A comparison of the cardiovascular actions of AQ 110 with those of isoprenaline and salbutamol
Author(s) -
FOGELMAN F.,
GRUNDY H. F.
Publication year - 1970
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/j.1476-5381.1970.tb08529.x
Subject(s) - isoprenaline , salbutamol , agonist , chemistry , catechol , adrenergic receptor , pharmacology , medicine , endocrinology , adrenergic , receptor , asthma , biochemistry , stimulation
Summary1 . AQ 110 is a β‐adrenoceptor agonist which, like isoprenaline and salbutamol, acts directly on the receptors. 2 . Compared with isoprenaline, AQ 110 has relatively stronger actions on bronchial and vascular smooth muscle (β 2 ‐adrenoceptors) than stimulant effects on heart muscle (β 1 ‐adrenoceptors). The β 2 ‐selectivity of AQ 110 is, however, much less than that of salbutamol, mainly due to the weak cardiac actions of the latter. 3 . At doses which were equipotent in decreasing the bronchoconstrictor effect produced by a standard dose of 5‐hydroxytryptamine, AQ 110 had marginally less hypotensive action than salbutamol and considerably less than isoprenaline. 4 . Although AQ 110, unlike salbutamol, possesses a catechol group it was found not to be a substrate for catechol‐O‐methyl transferase and this is considered to account for its significantly prolonged action, compared with isoprenaline, in vivo .